Skip to main content
. 2015 Jan 29;10(4):600–615. doi: 10.1016/j.celrep.2014.12.054

Figure 1.

Figure 1

ITZ Inhibits Viruses at the Genome Replication Stage

(A) BGM (CVB3, EV71, EMCV, ERAV) or HeLa R19 cells (HRV14, SAFV) were infected with virus at multiplicity of infection (MOI) 1 and treated with ITZ. Virus titers at 8 hr postinfection (p.i.) (10 hr for SAFV) were determined by endpoint dilution.

(B) Cell viability with MTS assay after 8 hr incubation with ITZ.

(C) BGM cells were transfected with RNA of subgenomic replicons pRib-LUC-CB3/T7 or pRLuc-M16.1 (EMCV) and treated with DMSO, 25 μM ITZ, or as positive controls 2 mM GuHCl or 80 μM dipyridamole, and luciferase levels were determined at the indicated time points.

Experiments were performed in triplicate and mean values ± SEM are shown; asterisks indicate statistical significance compared to mock treated controls. See also Figures S1 and S2.